AUTHOR INDEX

Abbott, R. D., 227
Achcar, J. A., 509
Ambrosioni, E., 361
Aragona, E., 345
Arnesen, E., 413
Auquier, A., 287

Bassein, L., 361
Baumrind, S., 47
Begg, C. B., 1, 129
Benini, L., 303
Bennett, B. M., 535
Berry, D. A., 497, 521
Bertelsen, C. A., 527
Blackwelder, W. C., 227
Boerma, G. J. M., 369
Borghi, C., 361
Bossi, A., 379
du Boulay, G. H., 311
Brenn, T., 413
Brookmeyer, R., 509
Bufalino, R., 265
Buring, J. E., 111
Byar, D. P., 255

Campbell, M. J., 353
Cascinelli, N., 265
Catford, J. C., 175, 189
Cavallini, G., 303
Charlton, J. R. H., 11
Charpak, Y., 279
Chastang, C., 279, 287
Chen, C.-H., 39
Chisholm, E. M., 337
Clayton, D., 327, 445
Commenges, D., 91
The Cooperative Group on CLL of Société Francais D'Hématologie, 287
The Cooperative Group on Lung Cancer (GETCB), 279
Costa, F. V., 361
Cottone, M., 345
Cuzick, J., 87

Dardanoni, G., 345
Decroix, G., 279
D'Souza, M. F., 11

Eberlein, K., 111

Filippazzo, M. G., 345

George, S. L., 39
Green, M. S., 53
Greenland, S., 117

Halperin, M., 227
Hennekens, C. H., 111
Hill, C., 295
Hougaard, P., 29
Hsieh, C.-C., 23
Hunter, W. G., 509

Innocent, P. R., 311

Jacobowitz, R., 227

Kaldor, J., 327
Kalish, L. A., 129
Kern, D. H., 527
Kline, J., 469
Korn, E. L., 47, 527

Lan, K. K. G , 227
Lanzarone, F., 345
Laplanche, A., 295
Lebeau, B., 279
Levin, B., 469
Lustbader, E. D., 425

Machin, D., 175, 189
Madsen, E. B., 29
Majumder, P. P., 163
Marenghini, A., 345
Marienfeld, C. J., 201
Maritz, J. S., 145
Marshall, R. J., 337
Marubini, E., 265
Micciolo, R., 303
Miettinen, O., 213
Milani, S., 379
Moolgavkar, S. H., 425
Morabito, A., 265
Morgenstern, H., 541
Morton, B. A., 311
Muir, C. S., 63
Muñoz, A., 457
Murrells, T. J., 175, 189
Mussi, A., 361

Nurminen, M., 213

Pagliaro, L., 345
Patti, C., 345
Pearson, L. M., 497
Piubello, W., 303
Plummer, D., 311

Rezvani, A., 295
Rosner, B., 111, 457

Schifflers, E., 63
Sciarrino, E., 345
Scuro, L. A., 303
Seal, J., 91
Shirley, E. A. C., 489
Shoop, G. L., 201
Silver, R., 11
Simonetti, R., 345
Slater, C., 397
Smans, M., 63
Smith, D. P., 155, 397
Smith, T. M. F., 175, 189
Sondak, V. K., 527
Speizer, F., 457
Stampfer, M. J., 111
Strocchi, E., 361

Tager, I., 457
Talamini, G., 303
Teather, D., 311
Tine, F., 345
Tooley, M., 11
Torasso, P., 317
Travade, P., 287
Tsutakawa, R. K., 201

Unkelbach, H. D., 77

Vantini, I., 303
Venzon, D. J., 425
Verter, J. I., 227

Walter, S. D., 437, 541
Wedel, H., 227
Weiss, S., 457
Willett, W., 111
Wills, K. M., 311
Wolf, T., 77

STATISTICS IN MEDICINE, VOL. 4, 553–557 (1985)

SUBJECT INDEX

((L) indicates subject discussed in Letter to the Editors)

Abortions, spontaneous, 469
Action potentials, neuron, 91
Additive hazard models in cohort studies, 353
Additivity, drug, 77
Age-specific rates, 63, 201
Agreement, interobserver, 47
Agreement index, majority, 47
Alcoholic pancreatitis, 303
Allocation of treatment in clinical trials, 129, 497
Analysis of pedigree, 163
Analysis of variability, 379
Analysis of variance, Friedman, 145
  random effects model, 145
Angiography, coronary, 53
Anthropometry, 379
Anticonvulsants, mixture of, 77
Artificial intelligence techniques, 317
Ascertainment bias in pedigree analysis, 163
Aspirin in prevention of cardiovascular disease, 111
Assay, predictive chemosensitivity, 527
Asthma, 145
Automatic recording devices for blood pressure, 361
Autoregressive model, time series, 457

Balance of treatments in clinical trials, 129
Bartholomew's test, 489
Bayesian methods, 201, 497, 509, 521
Beta carotene and cancer, 111
Bias, ascertainment, 163
  correction, 243(L), 244(L), 245(L), 437
  publication, in clinical trials, 1
  reference test, 53
  selection, 53
  validation group, 53
Biological factors in infant mortality, 175, 189
Birth cohort analysis, 63
Birth defects, surveillance of, 389(L), 390(L)
Blocked experiment design, 47
Blood pressure measurement, 361
Bone marrow transplantation, 1
Book Reviews
  L. A. Goldstone, *Understanding Medical Statistics*, 249
  D. Ingram and R. Block (Eds), *Mathematical Methods in Medicine, Part 1: Statistical and Analytical Techniques*, 393
  J. A. Ingelfinger, F. Mosteller, L. A. Thibodeau and J. H. Ware, *Biostatistics in Clinical Medicine*, 394
Book Reviews—contd.
  M. J. Gardner, P. D. Winter, C. P. Taylor and E. D. Acheson, *Atlas of Cancer Mortality in England and Wales, 1968–1978*, 549
  M. J. Gardner, P. D. Winter and D. J. P. Barker, *Atlas of Mortality from Selected Diseases in England and Wales, 1968–1978*, 549
Bootstrap resampling technique, 39
  hepatocellular, 345
Cancer, 87, 111
  bladder, 63, 201
  breast, 255
  chemotherapy, 527
  clinical trials, 1, 279, 287
  gastrointestinal, 337
  heptocellular, 345
  incidence, 63
  leukemia, 1, 39, 287, 509
  lung, 63, 117, 279
  melanoma, 63, 265, 527
  mortality, 201, 353
  prostate, 255
  stomach, 63, 201
  thyroid, 295
Cardiac arrest, 29
Cardiovascular mortality, 111, 397
Case-control studies, 327, 345, 425, 445
  power, 117
  size, 117
Cause-deleted life-tables, 155, 397
Censored observations, 29, 39, 155, 265, 279, 287, 303, 353, 413, 509
Cerebral disease, 311
Change-point problem, 91
Chemosensitivity assay, predictive, 527
Chemotherapy, 1, 527
Cirrhosis, 345
Classical linear models, 379
Clinical chemistry, 369
Clinical trials, allocation of treatment, 129, 489
  analysis of interactions, 111, 255
  aspirin and cardiovascular disease, 111
  balance of treatments in, 129
  beta carotene and cancer, 111
  cancer, 1, 279, 287
  community, 11
  compliance with treatment, 11
  crossover design, 361
  early termination of, 521
  efficiency, 129

Clinical trials, allocation of treatment—*contd.*
factional design, 111
group sequential, 521
hayfever, 11
interaction in, 111, 255
interim analysis of, 521
optimal design with dichotomous response, 497
power, 117
pragmatic, 11
publication bias, 1
qualitative interactions in, 111, 255
quantitative interactions in, 111, 255
randomization, 129, 387(L), 388(L)
sequential analysis, 521
size, 117, 247(L)
stratification, 129
subset analysis, 255
symptomatic conditions, 11
treatment allocation, 129, 489
treatment balance, 129
treatment–covariate interactions, 255
two-armed bandit, 497
two-staged design, 497
Clonogenic assay, 527
Cochran's test, 117
Cohort studies, 63, 295, 353
Colon polyp recurrence, 117
Combination preparations of drugs, 77
Community clinical trials, 11
Comparison of method, 361
ordered means, 87, 489, 543(L), 544(L), 546(L)
proportions, 541
rates, 213, 541
variances, 91
Competing risks, 29, 397
Compliance with treatment, 11
Computer aided diagnosis, 311, 317
Computerized tomography, 311
Confidence interval, difference in proportions, 23, 213
differences in rates, 213
odds ratio, 213
Confounding factors, 327, 387(L), 388(L)
Controls, external in cohort studies, 295, 353
Coronary angiography, 53
Coronary care, 387(L), 388(L)
Coronary disease, 53, 413
Correction for finite population, 237(L), 239(L)
Correlated proportions, 23
Correspondence analysis, 303
Cost-efficiency in estimating risk-ratio, 541
Covariates, time-dependent, 29
Cox proportional hazards regression model, 29, 39, 265, 279, 287, 303, 413
Crossover design, clinical trials, 361
Cross-sectional data, irregular, 63
surveys, 155
Cumulative sum (CUSUM) technique, 389(L), 390(L), 469

Death process, Poisson, 201
Dental malocclusion, 47
Dental plaque regrowth, 145
Design of clinical trials, factorial, 111
optimal for dichotomous response, 497
Detectable effect, smallest, in multivariate studies, 117
Diagnosis, computer-aided, 311, 317
statistical, 311
Diagnostic tests, for disease, 53, 535
for outliers in case-control studies, 425
Dichotomous response, optimal design of clinical trials, 497
Difference in proportions, confidence interval for, 23, 213
Disagreement index, pair, 47
Discharge policies after myocardial infarction, 29
Discharge sequences, neuronal, 91
Discriminant analysis, 413
Disease, staging of, 265, 279, 287
Distribution-free tests, 87, 145, 543(L), 544(L), 546(L)
Dose–response analysis, 77
Drug additivity, 77
potentiation, 77
Drugs joint action model, 77
Drugs, mixture of, 77
Duncan's multiple range test, 489
Dunnett's test, 489

Early termination of clinical trials, 521
Eastern Cooperative Oncology Group (ECOG), 1
ECG, exercise, 53
Efficacy of treatment, 1, 11, 387(L), 388(L)
Efficiency of clinical trials, 129
EM algorithm, 327, 445
Epidemiology, 23, 53, 63, 201, 213, 227, 237(L), 238(L), 239(L), 241(L), 295, 327, 337, 345, 353, 387(L), 388(L), 397, 413, 425, 445, 457, 469, 509
Estimates, empirical Bayes, 201
Estimation of mortality rates, 201
Evaluation of health care, 387(L), 388(L)
Evaluation of treatment in community trials, 11
Expected mortality, calculation of, 105(L), 106(L), 107(L), 109(L)
Expert systems, 311, 317
External controls in cohort studies, 295, 353

Factorial design, analysis of variability in, 379
Factorial design in clinical trials, 111
Factors, biological and social, in infant mortality, 175, 189
Finite population correction, 237(L), 239(L)
Follow-up studies, 157, 227, 295, 303, 509
Fourfold tables, odds ratio from, 437
Friedman analysis of variance, 145

Gamma sequences, neuronal discharge, 91
Generalized linear models, 353, 379
Genetics, human, 163
Group sequential analysis, clinical trials, 521
Group validation, bias, 53

Hayfever, 11
Hazard function, 29
Hazards model, additive and multiplicative, in cohort studies, 353
  proportional, 29, 39, 265, 279, 287, 295, 303, 413
Head circumference, at birth, 379
Health care, evaluation of, 387(L), 388(L)
Heart disease, 29, 53, 111, 397, 413
Heel length, crown, at birth, 379
Heterogeneity of variance, 379
Histogram, peri-stimulus time, 91
Homogeneity, test of, for counts, 469
Homoscedasticity, 379
Human genetics, 163
Hypothesis of indistinguishability, 337

Immunity test, cell mediated, 279
Immunotherapy, 279
Incidence, age specific, 63
Index, majority agreement, 47
Index, pair disagreement, 47
Indistinguishability hypothesis, 337
Infant mortality, 175, 189
Inheritance, 163
Instability in laboratory assay, 369
Interaction in clinical trial analysis, 111, 255
Intelligence, artificial, 317
Interface, man–machine, 311
Interim analysis in clinical trials, 521
International Bone Marrow Transplant Registry, 1
International Classification of Diseases, revisions for cardiovascular disease, 397
International Society for Clinical Biostatistics (ISCB),
  Fifth International Conference, San Marino
    committees, 253
    papers from, 255–391
    preface, 251
Inter-observer variation, 47
Inter-rater agreement, 47
Interval estimation, 23
Iron-binding proteins, 425
Irregular cross-sectional data, 63
Ischaemic heart disease, 397

Joint action model for combination preparations, 77
Jonckheere's test, 489

Kappa statistics, 47
Kepner and Randles test, 91
Knowledge representation in expert systems, 317

Laboratory determinations, reference values, 369
Laboratory monitoring, 369
Latency of neuronal response, 91
Latent-class model, 327, 445
Least significant difference test, 489
Leverage of matched-pairs, 425
Life tables, cause-deleted, 155, 397
Linear model, classical, 379
  generalized, 353, 379
Liver function, 317
Logistic regression model, 227, 237(L), 238(L), 239(L), 241(L), 243(L), 244(L), 245(L), 327, 337, 413, 425, 437
Logit models, 175, 189
Longitudinal data, autoregressive model for, 457

McNemar's test, 23
Majority agreement index, 47
Malocclusion, dental, 47
Mann–Whitney test, 87
Matched-pairs, 23, 425
Maximum-likelihood methods, 77, 91, 213, 243(L), 244(L), 245(L), 327, 337, 425, 437, 445
Means, ordered, 87, 489, 543(L), 544(L), 546(L)
Measurement errors in case-control studies, 445
Method comparison, 361
Misclassification, 327
Missing data in longitudinal studies, 457
Mixture ratio of drugs, 77(L)
Model additive hazards, 353
  autoregressive, 457
  classical linear, 379
  competing risks, 29
  Cox regression, 29, 39, 265, 279, 287, 303, 413
  generalized linear, 353, 379
  joint action, for drugs, 77
  latent class, 327, 445
  logistic regression, 227, 237(L), 238(L), 239(L), 241(L), 243(L), 244(L), 245(L), 327, 337, 413, 425, 437
  logit, 175, 189
  multiplicative hazards, 353
  proportional hazards, 29, 39, 265, 279, 287, 295, 303, 413
  random effects, 145, 201
  Weibull survival, 509
Model validation, 39
Monte Carlo stimulation, 163, 213, 227, 238(L), 239(L), 489
Monitoring, laboratory, 369
Mortality, analysis of, 155, 425
  cancer, 201, 353
  cardiovascular, 111, 397
  expected, calculation of, 105(L), 106(L), 107(L), 109(L)
  infant, 175, 189
  occupational, 105(L), 107(L), 109(L)
Mortality rates, 107(L), 201

Mortality ratio, standardized, 295
Multiple comparison tests, 489
Multiple probands, 163
Multiple range test, Duncan's, 489
Multiple risk factors, 117
Multiplicative hazards models in cohort studies, 353
Multivariate studies, smallest detectable effect in, 117
Myocardial infarction, hospital discharge policies after, 29

Neuronal discharge sequences, 91
Neuronal response, 91
Non-parametric tests, 87, 145, 543(L), 544(L), 546(L)

Observer agreement, 47
Occlusion, venous, 535
Occupational mortality, 105(L), 107(L), 109(L)
Odds ratio, 117, 175, 189, 213, 327, 437
Optimal allocation of treatment, 255, 497
Optimal design of clinical trials, 497
Ordered means, test for, 87, 489, 543(L), 544(L), 546(L)
Orthodontics, 47
Outliers in matched-pair studies, 425

Pair disagreement index, 47
Paired observations, 23
Pancreatitis, alcoholic, 303
Patient evaluation in community trials, 11
Pedigree analysis, 163
Penetrance, genetic, 163
Peri-stimulus time histogram, 91
Person-years method, 105(L), 106(L), 109(L)
Physicians Health Study (PHS), 111
Plaque regrowth, 145
Poisson death process, 201
Polyp, recurrence, colon, 117
Population correction, finite, 237(L), 239(L)
Potentiation, drug, 77
Power of case-control studies, 117
Power of clinical trials, 117
Pragmatic clinical trials, 11
Predictive chemosensitivity assay, 527
Predictive value of diagnostic tests, 53, 535
Probands, multiple, 163
Prognosis, short-term, after myocardial infarction, 29
Prognostic factors, 29, 39, 265, 279, 287, 303
Proportional hazards model, 29, 39, 265, 279, 287, 295, 303, 413
Proportions, comparison of, 541
  confidence interval for difference, 23, 213
  correlated, 23
  stratified, 213
Prospective studies, 155, 227, 295, 303, 509

Proteins, iron-bonding, 425
Publication bias in clinical trials, 1
Pulmonary function, 457

Qualitative interactions in clinical trials, 111, 255
Quality control in clinical chemistry, 369
Quantal responses, 77
Quantitative interactions in clinical trials, 111, 255

Random effects model, analysis of variance, 145
  mortality, 201
Randomization in clinical trials, 129, 387(L), 388(L)
Randomized clinical trials, *see* Clinical Trials
Range test, Duncan's multiple, 489
Rank tests, 87, 145, 543(L), 544(L), 546(L)
Rates, age-specific, 63, 201
Rates, comparison of, 213, 541
  difference in, 213
  mortality, standardized, 107(L), 295
  ratio of, 213
Ratio, mixture of drugs, 77
  odds, 117, 175, 189, 213, 327, 437
  of rates, 213
  standardized mortality, 295
Recording devices for blood pressure, automatic, 361
Reference test bias, 53
Regression, autoregressive model, 457
  Cox model, 29, 39, 265, 279, 287, 303, 413
  least squares, weighted, 353
  logistic, 227, 237(L), 238(L), 239(L), 241(L), 243(L), 244(L), 245(L), 327, 337, 413, 425, 437
  stepwise variable selection, 39, 413
Relative risk, 295, 327, 425, 445
Reliability, test-retest, 445
Resampling technique, bootstrap, 39
Residuals in matched-pair studies, 425
Risk factors, 117, 303, 327, 345, 413
Risk group, 39
Risk ratio, 117, 541

Sample, odds ratio estimation in small, 437
Sample size, 117, 247(L), 541
Sampling, non-random, in pedigree analysis, 163
Screening tests for coronary artery disease, 53
Selection bias, 53
Selection, stepwise, of variables, 39, 413
Sensitivity of diagnostic tests, 53, 535
Sensitivity of surveillance systems, 389(L), 390(L)
Sequences, gamma neuronal discharge, 91
Sequential analysis, group, 521
Sets surveillance technique, 389(L), 390(L)
Shewhart chart, 369
Simulation, Monte Carlo, 163, 213, 227, 238(L), 239(L), 489

Size of case-control studies, 117
clinical trials, 117, 247(L)
sample, comparison of rates, 541
Small sample estimates of odds ratio, 437
Smoking, cigarette, 117, 345, 457
Social factors in infant mortality, 175, 189
Specificity of diagnostic tests, 53, 535
Specificity of surveillance systems, 389(L), 390(L)
Sphygmomanometer, mercury, 361
Spontaneous abortions, 469
Staging of disease, 265, 279, 287
Standardized mortality rates, 107(L), 295
Statistical diagnosis, 311
Stepwise selection of variables, 39, 413
Stillbirths, 175, 189
Stratification in clinical trials, 129
Stratified proportions, 213
Subset analysis in clinical trials, 255
Surveillance systems, 389(L), 390(L), 469
Surveys, follow-up, 155, 227, 295, 303, 509
Survival analysis, 29, 39, 155, 265, 279, 287, 295, 303, 353, 397, 413, 509
Symptomatic conditions, clinical trials in, 11
Syphilis, 536

Termination early, of clinical trials, 521
Test, diagnostic, 53, 535
Test, distribution-free, 87, 145, 543(L), 544(L), 546(L)
Test, homogeneity, for counts, 469
Test, immunity, cell-mediated, 279
Test, reference, bias, 53
Test, trend, for ordered means, 87, 489, 543(L), 544(L), 546(L)
Test–retest reliability, 445
Time series, autoregressive, 457
Time trends in age-specific rates, 63
longitudinal data, 457
Time-dependent covariates, 29
Tomography, computerized, 311
Toxicity of treatment, 387(L), 388(L)
Toxicology, 489
Transformation of data, 145
Transplantation, bone-marrow, 1
Treatment, adaptation, 287
allocation in clinical trials, 129, 497
balance of, in clinical trials, 129
compliance with, 11
efficacy of, 1, 11, 387(L), 388(L)
evaluation of, in community trials, 11
optimal, 255
toxicity, 387(L), 388(L)
Treatment–covariate interaction, 255
Trend, test for ordered means, 87, 489, 543(L), 544(L), 546(L)
Tromsø Heart Study, 413
Two-armed bandit, 497
Two-stage design, clinical trials, 497

Validation group bias, 53
Validation, model, 39
Variability, analysis of, 379
Variables, stepwise selection, 39, 413
Variance, Friedman analysis of, 145
Variances, comparison of, 91
heterogeneity of, 379
Variation, inter-observer, 47
Venous occlusion, 535
Veteran's Administration Cooperative, Urological Research Group (VACURG), 255

Wald statistic, 117
Walker–Duncan estimates, 227, 237(L), 238(L), 239(L), 241(L)
Weibull distribution of survival times, 509
Wilcoxon rank sum test, 87, 145, 543(L), 544(L), 546(L)
William's test for ordered means, 489
World Health Organization, melanoma register, 265

Statistics in Medicine

Editors

T. Colton
L. S. Freedman
A. L. Johnson

JOHN WILEY & SONS
Chichester · New York · Brisbane · Toronto · Singapore
A Wiley–Interscience Publication

ISSN 0277–6715

Statistics in Medicine

EDITORS

Theodore Colton,
Boston University School of Public Health,
80 East Concord Street, Boston, Massachusetts 02118, U.S.A.

Laurence Freedman and **Tony Johnson,**
Medical Research Council Centre, Hills Road,
Cambridge CB2 2QH, U.K.

EDITORIAL BOARD

R. D'Agostino
Dept. of Mathematics,
Boston University, 264 Bay State Road,
Boston, MA 02215, USA

D. G. Altman
Clinical Research Centre,
Watford Road, Harrow,
Middlesex HA1 3UJ, UK

C. Anello
Division of Biometrics,
Bureau of Drugs,
Food & Drug Administration,
5600 Fishers Lane, Rockville,
MD 20857, USA

P. Armitage
Department of Biomathematics,
5 South Parks Road,
Oxford OX1 3UB, UK

J. R. Assenzo
Upjohn Research Laboratories,
Kalamazoo, Michigan 49001, USA

N. T. J. Bailey
Division d'Informatique Médicale,
Hôpital Cantonal Universitaire,
24, rue Micheli-du-Crest,
1211 Genève 4, Switzerland

M. Baum
Dept. of Surgery,
King's College Hospital Medical School,
Denmark Hill,
London SE5 8RX, UK

V. Beral
London School of Hygiene and Tropical Medicine,
Keppel Street,
London WC1E 7HT, UK

B. W. Brown, Jr
Division of Biostatistics,
Stanford Medical Center,
Stanford, CA 94305, USA

C. R. Buncher
Dept. of Epidemiology and Biostatistics,
University of Cincinnati Medical Center,
Mail Location 183,
Cincinnati, OH 45267, USA

D. Clayton
Dept. of Community Health,
Clinical Sciences Building,
Leicester Royal Infirmary,
PO Box 65, Leicester LE1 5WW, UK

K. Dietz
Universität Tübingen,
Institut für Medizinische Biometrie,
Westbahnhofstrasse 55,
7400 Tübingen 1, Germany

Sir Richard Doll
Green College at the Radcliffe Observatory,
Oxford OX2 6HG, UK

B. S. Everitt
Institute of Psychiatry,
De Crespigny Park,
Denmark Hill,
London SE5 8AF, UK

D. J. Finney
University of Edinburgh,
Dept. of Statistics,
James Clark Maxwell Building,
The King's Buildings, Mayfield Road,
Edinburgh EH9 3JZ, UK

A. J. Fox
Dept. of Mathematics,
The City University,
Northampton Square,
London EC1V 0HB, UK

J. Goldberg
Statistical Design and Analysis,
Medical Research Division,
American Cyanamid Company,
Lederle Laboratories,
Pearl River, NY 10965, USA

S. M. Gore
MRC Centre, Hills Road,
Cambridge CB2 2QH, UK

E. R. Greenberg
Dept. of Community Medicine,
Dartmouth Medical School,
Hanover, NH 03755, USA

J. D. F. Habbema
Dept. of Public Health and Social Medicine,
Erasmus University Rotterdam,
PO Box 1738,
3000 DR Rotterdam, The Netherlands

J. L. Haybittle
MRC Cancer Trials Office,
Hills Road,
Cambridge CB2 2QH, UK

C. Hennekens
Channing Laboratories,
Harvard Medical School,
25 Shattuck Street,
Boston, MA 02115, USA

B. Jarman
Lisson Grove Health Centre,
Gateforth Street,
London NW8 8EG, UK

N. Keiding
Statistical Research Unit,
Blegdamsvej 3,
DK-2200 Copenhagen N, Denmark

E. G. Knox
Dept. of Social Medicine,
The Medical School,
Birmingham B15 2TJ, UK

E. Marubini
Istituto di Biometria e Statistica Medica,
Università degli studi di Milano,
Via G Venezian 1, 20133 Milan, Italy

L. Massé
Ecole Nationale de la Santé Publique,
Avenue du Prof Léon Bernard,
Rennes 35043, France

C. K. McPherson
Dept. of Community Medicine and General Practice,
University of Oxford, 8 Keble Road,
Oxford OX1 3QN, UK

T. W. Meade
MRC Epidemiology and Medical Care Unit,
Northwick Park Hospital, Watford Road,
Harrow HA1 3UJ, UK

M. O'Fallon
Medical Research Statistics,
Mayo Clinic,
Rochester, MN 55901, USA

B. S. Pesternack
Dept. of Environmental Medicine
New York University School of Medicine,
550 First Avenue,
New York, NY 10016, USA

S. J. Pocock
Dept. of Clinical Epidemiology and General Practice,
Royal Free Hospital Medical School,
Pond Street,
London NW3 2PN, UK

C. Redmond
Dept. of Biostatistics,
School of Public Health,
University of Pittsburgh,
130 DeSoto Street,
Pittsburgh, PA 15261, USA

A. Rimm
Biostatistics/Epidemiology Division,
Dept. of Medicine,
Medical College of Wisconsin,
8701 Watertown Plank Rd,
Milwaukee, WI 53226, USA

B. Rosner
Channing Laboratories,
Harvard Medical School,
25 Shattuck Street,
Boston, MA 02115, USA

M. A. Schneiderman
6503 East Halbert Road,
Bethesda, MD 20817, USA

D. J. Spiegelhalter
MRC Centre, Hills Road,
Cambridge CB2 2QH, UK

I. Sutherland
MRC Biostatistics Unit,
MRC Centre, Hills Road,
Cambridge CB2 2QH, UK

J. Wittes
Mathematical and Applied Statistics Branch,
National Heart, Lung and Blood Institute,
Bethesda, MD 20205, U.S.A.

R. Zentgraf
Gödecke Aktiengesellschaft,
Postfach 569,
Mooswaldallee 1-9,
7800 Freiburg, Germany

C. Zippin
Dept. of Epidemiology,
School of Medicine,
University of California,
San Francisco, CA 94143, USA

JOHN WILEY & SONS
Chichester · New York · Brisbane · Toronto · Singapore
A Wiley–Interscience Publication

SMEDDA 4 1–557 (1985)
ISSN 0277–6715

Copyright © 1985 John Wiley & Sons Ltd.

COPYING OF ARTICLES

The code and the copyright notice appearing at the bottom of the first page of an article in this journal indicates the copyright owner's consent that copies of the article may be made for personal or internal use, or for the personal or internal use of specific clients, on the condition that the copier pay for the copying beyond that permitted by Sections 107 or 108 of the U.S. Copyright Law. The per-copy fee for each article appears after the dollar sign, and is to be paid through the Copyright Clearance Center, Inc. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale. Such permission requests, or other inquiries, should be addressed to the publisher.

Photo Typeset by Macmillan India Ltd. Printed by Galliard (Printers) Limited, Great Yarmouth, Norfolk, U.K.

CONTENTS

Volume 4, Issue Nos. 1–4

STATISTICS IN MEDICINE

Issue No. 1, January–March 1985

A Measure to Aid in the Interpretation of Published Clinical Trials 1
C. B. Begg

A Community Trial Strategy for Evaluating Treatment for Symptomatic Conditions 11
J. R. H. Charlton, M. F. D'Souza, M. Tooley and R. Silver

Note on Interval Estimation of the Difference Between Proportions from Correlated Series 23
C-C. Hsieh

Dynamic Evaluation of Short-term Prognosis After Myocardial Infarction 29
P. Hougaard and E. B. Madsen

The Bootstrap and Identification of Prognostic Factors Via Cox's Proportional Hazards Regression Model 39
C-H. Chen and S. L. George

Inter-rater Agreement Among Orthodontists in a Blocked Experiment 47
E. L. Korn and S. Baumrind

The Effect of Validation Group Bias on Screening Tests for Coronary Artery Disease 53
M. S. Green

Birth Cohort Analysis Using Irregular Cross-sectional Data: A Technical Note 63
E. Schifflers, M. Smans and C. S. Muir

Dose–Response Analysis of Combination Preparations 77
H. D. Unkelbach and T. Wolf

A Wilcoxon-type Test for Trend 87
J. Cuzick

The Analysis of Neuronal Discharge Sequences: Change-point Estimation and Comparison of Variances 91
D. Commenges and J. Seal

LETTERS TO THE EDITOR 105

ANNOUNCEMENT 110

Issue No. 2, April–June 1985

The 2 × 2 Factorial Design: Its Application to a Randomized Trial of Aspirin and Carotene in U.S. Physicians 111
M. J. Stampfer, J. E. Buring, W. Willett, B. Rosner, K. Eberlein and C. H. Hennekens

Indexed or abstracted by 'Current Contents' and other leading Indexing/Abstracting Services.

Power, Sample Size and Smallest Detectable Effect Determination for Multivariate Studies 117
S. Greenland

Treatment Allocation Methods in Clinical Trials: A Review 129
L. A. Kalish and C. B. Begg

Models and the Use of Signed Rank Tests 145
J. S. Maritz

Formulae for Cause-Deleted Life Tables 155
D. P. Smith

Comparison of Ascertainment-Bias Correction Schemes for Pedigrees Ascertained through Multiple Probands 163
P. P. Majumder

The Use of Logit Models to Investigate Social and Biological Factors in Infant Mortality. I: Methodology 175
T. J. Murrells, T. M. F. Smith, J. C. Catford and D. Machin

The Use of Logit Models to Investigate Social and Biological Factors in Infant Mortality. II: Stillbirths 189
T. J. Murrells, J. C. Catford, T. M. F. Smith and D. Machin

Empirical Bayes Estimation of Cancer Mortality Rates 201
R. K. Tsutakawa, G. L. Shoop and C. J. Marienfeld

Comparative Analysis of Two Rates 213
O. Miettinen and M. Nurminen

On the Use of the Logistic Model in Prospective Studies 227
M. Halperin, R. D. Abbott, W. C. Blackwelder, R. Jacobowitz, K. K. G. Lan, J. I. Verter and H. Wedel

LETTERS TO THE EDITOR 237

BOOK REVIEW 249

Issue No. 3, July–September 1985

Papers from the International Society for Clinical Biostatistics
Fifth International Meeting, September 1984

Preface 251

The ISCB 253

TREATMENT AND PROGNOSIS

Assessing Apparent Treatment–Covariate Interactions in Randomized Clinical Trials 255
D. P. Byar

Prognostic Factors for Stage I Melanoma of the Skin: A Review 265
N. Cascinelli, E. Marubini, A. Morabito and R. Bufalino

Prognostic Factors from a Randomized Clinical Trial in Resected Lung Cancer 279
C. Chastang, B. Lebeau, Y. Charpak, G. Decroix and The Cooperative Group on Lung Cancer (GETCB)

Critical Discussion of the Assessment of a Three-Stage Prognostic Classification for Chronic Lymphocytic Leukemia 287
C. Chastang, P. Travade, A. Auquier and The Cooperative Group on CLL of Société Francaise D'Hématologie

Comparison of the Mortality of a Cohort with the Mortality of a Reference Population in a Prognostic Study 295
C. Hill, A. Laplanche and A. Rezvani

Correspondence Analysis in a Study of the Clinical Evolution of Uncomplicated Chronic Relapsing Alcoholic Pancreatitis 303
R. Micciolo, I. Vantini, G. Cavallini, W. Piubello, G. Talamini, L. Benini and L. A. Scuro

COMPUTER DIAGNOSIS

Computer Assistance for C. T. Scan Interpretation and Cerebral Disease Diagnosis 311
D. Teather, B. A. Morton, G. H. du Boulay, K. M. Wills, D. Plummer and P. R. Innocent

Knowledge Based Expert Systems for Medical Diagnosis 317
P. Torasso

EPIDEMIOLOGY

Latent Class Analysis in Chronic Disease Epidemiology 327
J. Kaldor and D. Clayton

Hypothesis Testing in the Polychotomous Logistic Model with an Application to Detecting Gastrointestinal Cancer 337
R. J. Marshall and E. M. Chisholm

Assessment of Some Risk Factors for Hepatocellular Carcinoma: A Case Control Study 345
M. G. Filippazzo, E. Aragona, M. Cottone, G. Dardanoni, F. Lanzarone, A. Marenghini, C. Patti, E. Sciarrino, R. Simonetti, F. Tine and L. Pagliaro

Multiplicative and Additive Models with External Controls in a Cohort Study of Cancer Mortality 353
M. J. Campbell

LABORATORY MEDICINE AND BIOSTATISTICS

Comparison of Three Devices for Measuring Blood Pressure 361
L. Bassein, C. Borghi, F. V. Costa, E. Strocchi, A. Mussi and E. Ambrosioni

Are Routine Clinical Chemistry Analyses 'In Control' According to Shewhart's Technique? 369
G. J. M. Boerma

Linear Models for the Analysis of Variability in Factorial Designs: An Application to Anthropometric Indicators 379
A. Bossi and S. Milani

LETTERS TO THE EDITOR 387

BOOK REVIEWS 393

ANNOUNCEMENT 395

Issue No. 4, October–December 1985

The Pattern of Ischemic Heart Disease 1931–1980 397
D. P. Smith and C. Slater

Selecting Risk Factors: A Comparison of Discriminant Analysis, Logistic Regression and Cox's Regression Model Using Data from the Tromsø Heart Study 413
T. Brenn and E. Arnesen

Assessing the Adequacy of the Logistic Regression Model for Matched Case-Control Studies 425
S. H. Moolgavkar, E. D. Lustbader and D. J. Venzon

Small Sample Estimation of Log Odds Ratios from Logistic Regression and Fourfold Tables 437
S. D. Walter

Using Test–Retest Reliability Data to Improve Estimates of Relative Risk: An Application of Latent Class Analysis 445
D. Clayton

The Use of an Autoregressive Model for the Analysis of Longitudinal Data in Epidemiologic Studies 457
B. Rosner, A. Muñoz, I. Tager, F. Speizer and S. Weiss

The Cusum Test of Homogeneity with an Application in Spontaneous Abortion Epidemiology 469
B. Levin and J. Kline

The Value of Specialized Tests in Studies where Ordered Group Means are Expected 489
E. A. C. Shirley

Optimal Designs for Clinical Trials with Dichotomous Responses 497
D. A. Berry and L. M. Pearson

An Application of Bayesian Analysis to Medical Follow-up Data 509
J. A. Achcar, R. Brookmeyer and W. G. Hunter

Interim Analyses in Clinical Trials: Cassical vs. Bayesian Approaches 521
D. A. Berry

Analysis of the Clinical Utility of a Predictive Chemosensitivity Assay 527
E. L. Korn, V. K. Sondak, C. A. Bertelsen and D. H. Kern

On Tests for Equality of Predictive Values for *t* Diagnostic Procedures 535
B. M. Bennett

A Note on Optimal Sampling for the Comparison of Proportions or Rates 541
S. D. Walter and H. Morgenstern

LETTERS TO THE EDITOR 543

BOOK REVIEWS 549

ANNOUNCEMENT 550

Author Index 551

Subject Index 553